TGF-β pathway–targeting therapeutics such as TGF-β antibodies, TGF-β receptor kinase inhibitors, and TGF-β antisense oligonucleotides have been tested in preclinical animal models and clinical trials in cancer patients, including patients with bone metastases. Here, TGFB1 is linked to cancer.